Get a glimpse into our company and investor data—powered by the PitchBook Platform
Developer of novel vaccines designed to offer prevention from infectious diseases. The company's vaccines uses antigens, immunomodulators, nanoparticles and mAbs, enabling doctors to decrease the impact on public health of infections caused by drug-resistant pathogens.
You’re viewing a free company profile from the PitchBook Platform. To explore Vaxdyn’s full profile, request a free trial.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Seed Round | 01-Jan-2016 | $1.2M | 00.00 | Completed | Startup |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
---|---|---|---|---|---|---|
Caixa Capital Risc | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
Ministry of Economy | Other | 000 0000 | 000000 0 | |||
InSynchrony Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
Name | Title | Board Seat |
Contact Info |
---|---|---|---|
Manuel Montoya | Chief Operating Officer | ||
Michael McConnell Ph.D | Chief Scientific Officer | ||
Juan Infante Ph.D | Chief Executive Officer & Board Member |
Name | Representing | Role | Since | Contact Info |
---|---|---|---|---|
Juan Infante Ph.D | Self | Chief Executive Officer & Board Member | 000 0000 | |
Pilar Pérez-Romero Ph.D | Vaxdyn | Chairman of the Board | 000 0000 |